Vitamin K2 MK-7 and Heart Health: Why This Nutrient Deserves Attention
Katie Brouwer·Health journalist with a data-first approach. Compares vitamins, minerals, and supplements so you can make informed choices without the marketing noise.··8 min read
Vitamin K2 MK-7 and Heart Health: Why This Nutrient Deserves Attention
Most people think of vitamin K as the nutrient that helps blood clot. That is true, but there is a second role that is getting increasing attention from cardiovascular researchers: keeping calcium out of places it does not belong. Vitamin K2 MK-7 (menaquinone-7) sits at the center of that story, and the evidence is more substantial than many people realize.
Why Vitamin K2 Is Different From Vitamin K1
Vitamin K is a family of compounds, not a single nutrient. The form most people consume through leafy greens is phylloquinone, also called vitamin K1. The menaquinones, referred to collectively as vitamin K2, are a separate group found in fermented foods and animal products. Within the K2 family, MK-7 stands out for one practical reason: it stays in the bloodstream long enough to reach tissues outside the liver.
After a single dose, MK-7 remains detectable in serum for up to 48 to 96 hours. MK-4, another K2 form sold in supplements, is undetectable in serum after supplementation at typical doses. Vitamin K1 is preferentially taken up by the liver, leaving little for the cardiovascular system. That pharmacokinetic difference matters: only a nutrient that actually circulates to the vascular wall can activate the proteins that protect it.
The Rotterdam Study, which followed 4,807 adults over roughly a decade, found that higher dietary menaquinone intake was associated with a 57% reduction in coronary heart disease mortality and a 52% reduction in severe aortic calcification[2]. Vitamin K1 intake showed no such association. That divergence has driven researchers to focus specifically on K2, and increasingly on MK-7 as the most bioavailable supplemental form.
A 2019 meta-analysis pooling data from 222,592 participants found that higher menaquinone intake was associated with a 30% lower risk of coronary heart disease (HR 0.70)[3].
The MGP Mechanism: How MK-7 Protects Arteries
The most compelling reason to pay attention to MK-7 comes down to a single protein called matrix Gla protein (MGP). MGP is produced by smooth muscle cells in artery walls and is the body's primary local brake on vascular calcification. The catch is that MGP only works when it is properly activated through a process called gamma-carboxylation, which requires vitamin K2 as a cofactor.
When vitamin K2 levels are insufficient, MGP remains in its inactive form, known as desphospho-uncarboxylated MGP (dp-ucMGP). In this state, it cannot bind calcium effectively, and calcium salts accumulate in the arterial wall. This process stiffens arteries over time, elevates pulse pressure, and is a recognized risk factor for heart attack, stroke, and heart failure. Elevated plasma dp-ucMGP is now considered an independent biomarker of cardiovascular risk: the 2019 meta-analysis found that high dp-ucMGP levels were associated with a 96% higher risk of CVD mortality (HR 1.96) and an 84% higher risk of all-cause mortality (HR 1.84).
Frequently Asked Questions
This content is for informational purposes only and is not intended as medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before starting any supplement or making changes to your health regimen.
KB
Katie Brouwer
Health journalist with a data-first approach. Compares vitamins, minerals, and supplements so you can make informed choices without the marketing noise.
Health journalist with a data-first approach. Compares vitamins, minerals, and supplements so you can make informed choices without the marketing noise.
MK-7 supplementation directly addresses this. In a dose-response randomized controlled trial, 180 mcg per day of MK-7 for 12 weeks reduced dp-ucMGP by 31%, while 360 mcg per day reduced it by 46%[6]. The osteocalcin carboxylation ratio, a related marker, improved by 60 to 74%. These numbers confirm that MK-7 at supplemental doses is not just theoretically plausible as a vascular protector: it measurably shifts the body's calcification-inhibitory machinery into a more active state.
Think of MGP as a security guard stationed in artery walls. Without vitamin K2, the guard is present but off duty. MK-7 gives it the tools to do the job.
What the Clinical Trials Show for Arterial Stiffness
Arterial stiffness, measured by carotid-femoral pulse wave velocity (cfPWV), is a well-validated surrogate marker for cardiovascular risk. Several randomized trials have examined whether MK-7 supplementation can slow its progression.
The most rigorous trial enrolled 244 healthy postmenopausal women and assigned them to 180 mcg per day of MK-7 or placebo for three years[1]. The MK-7 group showed significant improvements in cfPWV and Stiffness Index beta. Effects were most pronounced in women with above-median baseline stiffness, suggesting that those already experiencing vascular aging may have the most to gain. dp-ucMGP levels fell by 50% relative to placebo.
A 2025 randomized trial in 165 postmenopausal women found that 180 mcg per day for 12 months significantly attenuated vascular stiffness and reduced brachial blood pressure[10]. dp-ucMGP reductions were again confirmed, linking the supplement to the biomarker to the functional outcome.
A 2023 multicenter trial in hemodialysis patients used 375 mcg per day for 24 weeks[7]. The overall group showed no significant pulse wave velocity improvement, but the diabetic subgroup did: cfPWV fell by 10.0% versus a 3.8% increase in controls (p<0.008). A high-dose trial of 720 mcg per day of MK-7 plus vitamin D for 24 months in elderly men with advanced aortic valve calcification found no significant effect on disease progression[8]. That null result suggests earlier intervention, before calcification is severe, is where the evidence is strongest.
Coronary Calcification and CHD Risk in Population Studies
Beyond arterial stiffness trials, population-level data build a consistent case for the link between vitamin K2 status and cardiovascular outcomes. A cross-sectional study of 564 postmenopausal women found that those in the highest quartile of menaquinone intake had a 20% lower relative risk of coronary artery calcification compared to those in the lowest quartile (RR 0.80, p<0.05)[5]. Vitamin K1 showed no protective association in the same analysis.
The Rotterdam Study followed 4,807 adults for roughly a decade and found that those with the highest menaquinone intake had substantially lower coronary heart disease mortality (RR 0.43) and were 52% less likely to have severe aortic calcification (OR 0.48)[2]. These are large effect sizes for a dietary variable, and they held after adjustment for traditional cardiovascular risk factors. A prospective study of 16,057 women found a 9% lower CHD hazard for each additional 10 mcg per day of dietary K2 (HR 0.91), with the association driven by longer-chain menaquinones including MK-7[4].
The 2019 meta-analysis pooling 222,592 participants confirmed that higher menaquinone intake was associated with a 30% lower CHD risk (HR 0.70), consistent across European and Asian populations[3]. Observational data cannot establish causation, and dietary confounding is a reasonable concern. The convergence across multiple large cohorts, combined with the well-characterized MGP mechanism, makes this association more than circumstantial.
Who Is Most Likely to Benefit, and Who Should Be Cautious
The clearest evidence for cardiovascular benefit comes from postmenopausal women. Multiple randomized trials have demonstrated improvements in arterial stiffness in this group, and their risk profile makes them plausible candidates for subclinical vascular calcification. Postmenopausal estrogen decline is associated with accelerated arterial aging, and low dietary K2 intake may compound that risk.
People who eat few fermented foods are also more likely to have low dietary K2 intake. Natto, the richest food source of MK-7, is uncommon outside East Asian diets. Individuals with chronic kidney disease face a specific problem: impaired K2 metabolism combined with accelerated vascular calcification, as reflected in the higher doses used in the dialysis trial[7].
One safety warning applies unconditionally. People taking warfarin, acenocoumarol, or any vitamin K antagonist (VKA) anticoagulant must not take MK-7 supplements without medical supervision. Vitamin K2 promotes coagulation factor carboxylation, directly counteracting what VKAs are designed to suppress. A randomized trial showed that even 10 to 20 mcg per day of MK-7 caused clinically relevant INR reductions in 40 to 60% of anticoagulated subjects[9]. At 45 mcg per day, mean INR fell by roughly 40%. Standard supplement doses of 180 mcg per day or more would be expected to significantly undermine anticoagulation.
For people not on anticoagulants, the safety profile appears favorable. Trials using 180 to 720 mcg per day for up to three years have not reported serious adverse events attributable to MK-7[1][7][8][10].
Practical Considerations for Vitamin K2 MK-7
The most commonly used dose in clinical trials is 180 mcg per day, and this is the level at which multiple RCTs have demonstrated improvements in arterial stiffness[1][10]. Lower doses of 45 mcg or less are unlikely to deliver the same tissue-level effect. Higher doses of 360 to 720 mcg have been used in kidney disease populations, but those require medical oversight.
MK-7 is fat-soluble and is better absorbed with a fat-containing meal. Natto, the richest food source, provides several hundred micrograms per small serving, though it is uncommon outside East Asian diets. Aged cheeses, egg yolks, and grass-fed dairy contain some K2 but at far lower amounts.
Pairing MK-7 with vitamin D3 is common, since vitamin D promotes calcium absorption from the gut while K2 directs that calcium toward bone and away from arteries. The combination is biologically plausible, though the high-dose trial that combined them in advanced disease found no significant benefit[8]. The research on vitamin D and cardiovascular health is worth exploring alongside MK-7, as is the evidence on magnesium and blood pressure for those interested in nutrient-level cardiovascular support.
Frequently Asked Questions
Q. What is vitamin K2 MK-7 and how is it different from regular vitamin K?
Vitamin K2 MK-7 (menaquinone-7) is a specific form of vitamin K found mainly in fermented foods. Most people associate vitamin K with vitamin K1 (phylloquinone), which is found in leafy greens and primarily supports blood clotting in the liver. MK-7 has a much longer half-life of 48 to 96 hours and reaches extrahepatic tissues including the arteries, where it activates a calcification-inhibiting protein called matrix Gla protein. This is why the cardiovascular evidence for MK-7 is considerably stronger than for vitamin K1[2][3].
Q. Can vitamin K2 MK-7 unclog arteries or reverse existing calcification?
Research suggests MK-7 is most effective at slowing the progression of early arterial stiffness, not reversing established, severe calcification. A 2022 randomized trial using a high dose of 720 mcg per day for two years found no significant reduction in aortic valve calcification in elderly men who already had advanced disease[8]. The strongest positive results come from trials in people with subclinical or early-stage vascular stiffness. Current evidence points toward MK-7 as a preventive tool rather than a treatment for advanced arterial disease.
Q. How long does it take to see cardiovascular benefits from vitamin K2 MK-7?
Most successful trials used daily supplementation for 12 months to three years. The three-year randomized trial by Knapen et al. found significant improvements in pulse wave velocity and arterial stiffness[1], and the 2025 trial by de Vries et al. found meaningful effects after 12 months[10]. Biomarker changes, such as reductions in dp-ucMGP, can occur within weeks of starting supplementation, but clinical outcomes like measurable arterial stiffness improvement appear to require sustained use over months to years.
Q. Is vitamin K2 MK-7 safe to take if I am on warfarin?
No. People taking warfarin, acenocoumarol, or any vitamin K antagonist (VKA) anticoagulant should not take MK-7 supplements without medical supervision. Even low doses of 10 to 45 mcg per day have been shown to meaningfully reduce INR in anticoagulated patients[9]. Standard supplement doses of 180 mcg per day would be expected to significantly interfere with anticoagulation therapy. This interaction is well-documented and represents a serious safety concern. Always consult your prescribing clinician before taking any vitamin K supplement.
Q. What dose of vitamin K2 MK-7 is used in research?
The most common dose in clinical trials is 180 mcg per day, and this is the level at which multiple randomized controlled trials have demonstrated improvements in arterial stiffness and reductions in the cardiovascular biomarker dp-ucMGP[1][6][10]. Higher doses of 360 to 720 mcg per day have been used in populations with kidney disease or advanced calcification, but these should be discussed with a clinician. Most research indicates that 180 mcg per day, taken with a fat-containing meal, is sufficient to raise serum MK-7 to physiologically active levels.
References
[1] Knapen MHJ et al., "Menaquinone-7 supplementation improves arterial stiffness in healthy postmenopausal women. A double-blind randomised clinical trial," Thrombosis and Haemostasis, 2015. DOI: 10.1160/TH14-08-0675
[2] Geleijnse JM et al., "Dietary intake of menaquinone is associated with a reduced risk of coronary heart disease: the Rotterdam Study," Journal of Nutrition, 2004. DOI: 10.1093/jn/134.11.3100
[3] Chen HG et al., "Association of vitamin K with cardiovascular events and all-cause mortality: a systematic review and meta-analysis," European Journal of Nutrition, 2019. DOI: 10.1007/s00394-019-01998-3
[4] Gast GCM et al., "A high menaquinone intake reduces the incidence of coronary heart disease," Nutrition, Metabolism and Cardiovascular Diseases, 2009. DOI: 10.1016/j.numecd.2008.10.004
[5] Beulens JWJ et al., "High dietary menaquinone intake is associated with reduced coronary calcification," Atherosclerosis, 2009. DOI: 10.1016/j.atherosclerosis.2008.07.010
[6] Dalmeijer GW et al., "The effect of menaquinone-7 supplementation on circulating species of matrix Gla protein," Atherosclerosis, 2012. DOI: 10.1016/j.atherosclerosis.2012.09.019
[7] Naiyarakseree N et al., "Effect of Menaquinone-7 Supplementation on Arterial Stiffness in Chronic Hemodialysis Patients: A Multicenter Randomized Controlled Trial," Nutrients, 2023. DOI: 10.3390/nu15112422
[8] Diederichsen ACP et al., "Vitamin K2 and D in Patients With Aortic Valve Calcification: A Randomized Double-Blinded Clinical Trial," Circulation, 2022. DOI: 10.1161/CIRCULATIONAHA.121.057008
[9] Theuwissen E et al., "Effect of low-dose supplements of menaquinone-7 (vitamin K2) on the stability of oral anticoagulant treatment: dose-response relationship in healthy volunteers," Journal of Thrombosis and Haemostasis, 2013. DOI: 10.1111/jth.12203
[10] de Vries F et al., "Effects of One-Year Menaquinone-7 Supplementation on Vascular Stiffness and Blood Pressure in Post-Menopausal Women," Nutrients, 2025. DOI: 10.3390/nu17050815
This content is for informational purposes only and is not intended as medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before starting any supplement or making changes to your health regimen.
